NeuroPhage 公司新药有很好的效果

mumucu · 发表于 2012-10-31 11:43:21

NeuroPhage Pharmaceuticals Has Positive Results With Neurodegenerative Disease Therapy
October 17, 2012
Many neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and ALS, are characterized by aggregates of proteins. Many companies have tried to target the disassembly of these protein aggregates; however, few have made progress using this approach, until now. Cambridge, MA-based NeuroPhage Pharmaceuticals just reported positive results in a pre-clinical study using their anti-protein aggregate therapy, NPT001. Neurophage tested NPT001 in a pre-clinical model of Parkinson’s disease. In this model, NPT001, was able to clear the -synuclein protein aggregates, as well as restore normal function to neurons. The studies were performed in the laboratory of Dr. Eliezer Masliah, a professor at the University of California San Diego. NeuroPhage is one of the newest teams competing for the $1M ALS Treatment Prize, and hopefully, they will reproduce this positive result with NPT001 in ALS!
大体就是说这个公司代号NPT001的新药在临床前实验阶段获得积极的效果。此药能够有效防止治病蛋白的聚集，恢复神经元的正常功能。不知道此药什么时候能够上市啊。

融化、渐冻ALS · 发表于 2012-10-31 11:50:04

有希望了哈

迎春花 · 发表于 2012-10-31 11:58:57

啥时上市啊？怕等不及了呀。。。

断翅的鹰 · 发表于 2012-10-31 12:38:14

临床？几期了？

虚度快乐 · 发表于 2012-10-31 13:26:36

:victory:

/pig_fly_pig · 发表于 2012-10-31 13:27:07

NeuroPhage对神经退行性疾病的药物资料有积极的结果
2012年10月17日
许多神经退行性疾病，包括老年痴呆症，帕金森氏病，与肌萎缩侧索硬化症（ALS），其特点是某种蛋白质聚集太多影响神经细胞功能。许多公司试图消灭这些蛋白质；然而，直到现在，很少有取得明显的进展。前不久，剑桥大学医学院报告，他们使用基于NeuroPhage技术的药品在消灭这些蛋白质，保护体内的神经细胞取得了明显的临床实验效果。这个测试名字叫做npt001。在帕金森病临床实验中，npt001，能够明确的-突触核蛋白的蛋白质总量，以及恢复正常功能的神经元。本研究是在实验室中完成的加利福尼亚大学圣地亚哥分校伊利瑟博士、教授完成的。NeuroPhage这个药物是上面教授为了竞逐一百万美元治疗肌萎缩侧索而进行的，希望他们能将这一成果npt001在肌萎缩侧索硬化症ALS上面！

不晓得翻译得怎样。